Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 367

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Open access
Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Rossiev, Viktor, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiri, Yablokova, Vera, Krejcy, Kurt, Grohmann-Izay, Barbara, Hasselbalch, Hans C, Kralovics, Robert, Kiladjian, Jean-Jacques, Bauer, Franz, Berbec, Nicoleta, Besses Raebel, Carlos, Borbenyi, Zita, Bumbea, Horia, Buxhofer-Ausch, Veronika, Calbecka, Malgorzata, Cayssials-Caylus, Emilie, Cazzola, Mario, Cerna, Olga, Cucuianu, Andrei, Dima, Delia Monica, Forjan, Ernst, Gheorghita, Emanuil, Greil, Richard, Hatalova, Antonia, Hrubisko, Mikulas, Jakucs, Janos, Kaplan, Polina, Klymenko, Sergiy, Koschmieder, Steffen, Lazaroiu, Mihaela, Lysa, Tamila, Masliak, Zvenyslava, Masszi, Tamas, Mihaylov, Georgi, Myasnikov, Alexander, Platzbecker, Uwe, Puyade, Mathieu, Rey, Jerome, Roy, Lydia, Schwarz, Jiri, Skotnicki, Aleksander, Sokolova, Irina, Soroka-Wojtaszko, Maria, Starzak-Gwozdz, Jolanta, Stoeva, Vera, Torregrosa-Diaz, Jose Miguel, Vallova, Anna, Volodicheva, Elena, Warzocha, Krzysztof, Willenbacher, Ella, Wolf, Dominik·2020·The Lancet Haematology

Abstract

BACKGROUND The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment. METHODS PROUD-PV and its extension study, CONTINUATION-PV, were phase 3, randomised, controlled, open-label, trials done in 48 clinics in Europe. Patients were eligible if 18 years or older with early stage polycythaemia vera (no history of cytoreductive treatment or less than 3 years of previous hydroxyurea treatment) diagnosed by WHO's 2008 criteria. Patients were randomly assigned 1:1 to ropeginterferon alfa-2b (subcutaneously every 2 weeks, starting at 100 μg) or hydroxyurea (orally starting at 500 mg/day). After 1 year, patients could opt to enter the extension part of the trial, CONTINUATION-PV. The primary endpoint in PROUD-PV was non-inferiority of ropeginterferon alfa-2b versus hydroxyurea regarding complete haematological response with normal spleen size (longitudinal diameter of ≤12 cm for women and ≤13 cm for men) at 12 months; in CONTINUATION-PV, the coprimary endpoints were complete haematological response with normalisation of spleen size and with improved disease burden (ie, splenomegaly, microvascular disturbances, pruritus, and headache). We present the final results of PROUD-PV and an interim analysis at 36 months of the CONTINUATION-PV study (per statistical analysis plan). Analyses for safety and efficacy were per-protocol. The trials were registered on EudraCT, 2012-005259-18 (PROUD-PV) and 2014-001357-17 (CONTINUATION-PV, which is ongoing). FINDINGS Patients were recruited from Sept 17, 2013 to March 13, 2015 with 306 enrolled. 257 patients were randomly assigned, 127 were treated in each group (three patients withdrew consent in the hydroxyurea group), and 171 rolled over to the CONTINUATION-PV trial. Median follow-up was 182·1 weeks (IQR 166·3-201·7) in the ropeginterferon alfa-2b and 164·5 weeks (144·4-169·3) in the standard therapy group. In PROUD-PV, 26 (21%) of 122 patients in the ropeginterferon alfa-2b group and 34 (28%) of 123 patients in the standard therapy group met the composite primary endpoint of complete haematological response with normal spleen size. In CONTINUATION-PV, complete haematological response with improved disease burden was met in 50 (53%) of 95 patients in the ropeginterferon alfa-2b group versus 28 (38%) of 74 patients in the hydroxyurea group, p=0·044 at 36 months. Complete haematological response without the spleen criterion in the ropeginterferon alfa-2b group versus standard therapy group were: 53 (43%) of 123 patients versus 57 (46%) of 125 patients, p=0·63 at 12 months (PROUD-PV), and 67 (71%) of 95 patients versus 38 (51%) of 74 patients, p=0·012 at 36 months (CONTINUATION-PV). The most frequently reported grade 3 and grade 4 treatment-related adverse events were increased γ-glutamyltransferase (seven [6%] of 127 patients) and increased alanine aminotransferase (four [3%] of 127 patients) in the ropeginterferon alfa-2b group, and leucopenia (six [5%] of 127 patients) and thrombocytopenia (five [4%] of 127 patients) in the standard therapy group. Treatment-related serious adverse events occurred in three (2%) of 127 patients in the ropeginterferon alfa-2b group and five (4%) of 127 patients in the hydroxyurea group. One treatment-related death was reported in the standard therapy group (acute leukaemia). INTERPRETATION In patients with early polycythaemia vera, who predominantly presented without splenomegaly, ropeginterferon alfa-2b was effective in inducing haematological responses; non-inferiority to hydroxyurea regarding haematological response and normal spleen size was not shown at 12 months. However, response to ropeginterferon alfa-2b continued to increase over time with improved responses compared with hydroxyurea at 36 months. Considering the high and durable haematological and molecular responses and its good tolerability, ropeginterferon alfa-2b offers a valuable and safe long-term treatment option with features distinct from hydroxyurea. FUNDING AOP Orphan Pharmaceuticals AG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(19)30236-4

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 367

Metadata

Authors
Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-Kyuchukova, L., Egyed, M., Rossiev, V., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Krejcy, K., Grohmann-Izay, B., Hasselbalch, H. C., Kralovics, R., Kiladjian, J.-J., Bauer, F., Berbec, N., Besses Raebel, C., Borbenyi, Z., Bumbea, H., Buxhofer-Ausch, V., Calbecka, M., Cayssials-Caylus, E., Cazzola, M., Cerna, O., Cucuianu, A., Dima, D. M., Forjan, E., Gheorghita, E., Greil, R., Hatalova, A., Hrubisko, M., Jakucs, J., Kaplan, P., Klymenko, S., Koschmieder, S., Lazaroiu, M., Lysa, T., Masliak, Z., Masszi, T., Mihaylov, G., Myasnikov, A., Platzbecker, U., Puyade, M., Rey, J., Roy, L., Schwarz, J., Skotnicki, A., Sokolova, I., Soroka-Wojtaszko, M., Starzak-Gwozdz, J., Stoeva, V., Torregrosa-Diaz, J. M., Vallova, A., Volodicheva, E., Warzocha, K., Willenbacher, E., & Wolf, D.
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2020-03
Volume
7
Issue
3
Pages
e196-e208
ISSN
2352-3026 (ISSN-L)
OpenAlex
W3003423609
Cited by
367
References
24
FWCI
22.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. https://app.cochat.ai/papers/10.1016/s2352-3026(19)30236-4
The paper
Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva-Kyuchukova, L., Egyed, M., Rossiev, V., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Krejcy, K., Grohmann-Izay, B., Hasselbalch, H. C., Kralovics, R., Kiladjian, J.-J., Bauer, F., . . . Wolf, D. (2020). Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(19)30236-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.